113 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Active, not recruiting Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
3 Recruiting A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anthracycline-based chemotherapy;   Drug: pertuzumab [Perjeta];   Drug: taxane;   Drug: trastuzumab emtansine [Kadcyla];   Drug: trastuzumab [Herceptin]
4 Active, not recruiting Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Non-Hodgkins Lymphoma;   B-cell Lymphoma;   Waldenstrom's Macroglobulinemia;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Primary Central Nervous System Lymphoma
Intervention: Drug: Ublituximab
5 Active, not recruiting Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant interferon alfa
6 Active, not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Conditions: Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: vinorelbine tartrate;   Drug: cisplatin;   Drug: docetaxel;   Drug: pemetrexed disodium;   Biological: bevacizumab;   Other: questionnaire administration;   Other: laboratory biomarker analysis
7 Recruiting A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant;   Drug: BKM120;   Drug: BKM120 matching placebo
8 Terminated Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung;   Lung Cancer;   Neoplasms, Lung;   Neoplasms, Pulmonary
Interventions: Drug: talabostat;   Drug: pemetrexed
9 Completed
Has Results
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine;   Drug: fulvestrant
10 Recruiting A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo
11 Recruiting Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
Condition: Melanoma
Interventions: Drug: LGX818;   Drug: LGX818+MEK162;   Drug: vemurafenib
12 Completed
Has Results
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Chemotherapy-Induced Thrombocytopenia;   Non-Small Cell Lung Cancer;   Cancer;   Lung Neoplasms;   Oncology;   Solid Tumors;   Thrombocytopenia
Interventions: Biological: Romiplostim;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin
13 Active, not recruiting S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Conditions: Metastatic Cancer;   Prostate Cancer
Interventions: Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
14 Completed A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small-cell Lung Carcinoma
Intervention: Drug: Tarceva (erlotinib HCl)
15 Completed
Has Results
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Abraxane
16 Completed Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Ezatiostat Hydrochloride
17 Terminated
Has Results
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: doxorubicin HCl liposome
18 Unknown  Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Condition: Breast Cancer
Intervention: Drug: Bevacizumab (drug), Herceptin (drug)
19 Active, not recruiting Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: tamoxifen citrate;   Radiation: Radiation Therapy
20 Active, not recruiting Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years